Guido Francini

Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial.

S. Sestini, M. Sabatino, G. Francini, 2001, European journal of cancer.

Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.

B. Vincenzi, D. Santini, G. Tonini, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.

R. Petrioli, S. Bruni, S. Marsili, 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.